Brainstorm Cell Therapeutics Inc. (BCLI) Given a $8.00 Price Target at Maxim Group


The brokerage presently has a "buy" rating on the biotechnology company's stock. Maxim Group's price objective points to a potential upside of 81.00% from the company's current price.



from Biotech News